172 related articles for article (PubMed ID: 24012820)
1. Increased teicoplanin doses are associated with improved serum levels but not drug toxicity.
Matthews PC; Chue AL; Wyllie D; Barnett A; Isinkaye T; Jefferies L; Lovering A; Scarborough M
J Infect; 2014 Jan; 68(1):43-9. PubMed ID: 24012820
[TBL] [Abstract][Full Text] [Related]
2. Factors on trough teicoplanin levels, associations between levels, efficacy and safety in patients with gram-positive infections.
Wang T; Li N; Hu S; Xie J; Lei J; Wang Y; Zheng X; Xing J; Dong Y
Int J Clin Pharmacol Ther; 2015 May; 53(5):356-62. PubMed ID: 25828639
[TBL] [Abstract][Full Text] [Related]
3. Optimal teicoplanin loading regimen to rapidly achieve target trough plasma concentration in critically ill patients.
Li H; Gao L; Zhou L; Wang Y; Li Q; Wang J; Chen T; Zhang Y; Wang T; Shi Q
Basic Clin Pharmacol Toxicol; 2020 Mar; 126(3):277-288. PubMed ID: 31608579
[TBL] [Abstract][Full Text] [Related]
4. Loading dose required to achieve rapid therapeutic teicoplanin trough plasma concentration in patients with multidrug-resistant gram-positive infections.
Wang JT; Liao HI; Wu Lin FL; Chang SC
Basic Clin Pharmacol Toxicol; 2012 May; 110(5):416-20. PubMed ID: 22309355
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic Drug Level Monitoring of Teicoplanin in Korean Pediatric Patients with Normal versus Impaired Renal Function.
Choi JS; Kim JM; Kim D; Kim SH; Cho H; Park HD; Lee SY; Kang CI; Kim YJ
J Korean Med Sci; 2020 Nov; 35(46):e376. PubMed ID: 33258328
[TBL] [Abstract][Full Text] [Related]
6. Recommendations to achieve rapid therapeutic teicoplanin plasma concentrations in adult hospitalised patients treated for sepsis.
Brink AJ; Richards GA; Cummins RR; Lambson J;
Int J Antimicrob Agents; 2008 Nov; 32(5):455-8. PubMed ID: 18718742
[TBL] [Abstract][Full Text] [Related]
7. Evaluating the optimal dose of teicoplanin with therapeutic drug monitoring: not too high for adverse event, not too low for treatment efficacy.
Kim SH; Kang CI; Huh K; Cho SY; Chung DR; Lee SY; Kim YJ; Peck KR
Eur J Clin Microbiol Infect Dis; 2019 Nov; 38(11):2113-2120. PubMed ID: 31372903
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of Teicoplanin Trough Values After the Recommended Loading Dose in Children With Associated Safety Analysis.
Yamada T; Kubota T; Yonezawa M; Nishio H; Kanno S; Yano T; Kobayashi D; Egashira N; Takada H; Hara T; Masuda S
Pediatr Infect Dis J; 2017 Apr; 36(4):398-400. PubMed ID: 27977550
[TBL] [Abstract][Full Text] [Related]
9. Teicoplanin pharmacokinetics in pediatric patients.
Dufort G; Ventura C; Olivé T; Ortega JJ
Pediatr Infect Dis J; 1996 Jun; 15(6):494-8. PubMed ID: 8783345
[TBL] [Abstract][Full Text] [Related]
10. Variations of teicoplanin concentrations in neutropenic patients.
Gimenez F; Leblond V; Nguyen J; Serrand P; Binet JL; Grosset J; Thuillier A
J Clin Pharm Ther; 1997 Jun; 22(3):187-90. PubMed ID: 9447473
[TBL] [Abstract][Full Text] [Related]
11. Age- and gender-related differences in teicoplanin levels in paediatric patients.
Strenger V; Hofer N; Rödl S; Hönigl M; Raggam R; Seidel MG; Dornbusch HJ; Sperl D; Lackner H; Schwinger W; Sovinz P; Benesch M; Urlesberger B; Urban C
J Antimicrob Chemother; 2013 Oct; 68(10):2318-23. PubMed ID: 23702837
[TBL] [Abstract][Full Text] [Related]
12. Determination of teicoplanin trough concentration target and appropriate total dose during the first 3 days: a retrospective study in patients with MRSA infections.
Matsumoto K; Kanazawa N; Ikawa K; Fukamizu T; Shigemi A; Yaji K; Shimodozono Y; Morikawa N; Takeda Y; Yamada K
J Infect Chemother; 2010 Jun; 16(3):193-9. PubMed ID: 20195882
[TBL] [Abstract][Full Text] [Related]
13. Tolerability and Plasma Drug Level Monitoring of Prolonged Subcutaneous Teicoplanin Treatment for Bone and Joint Infections.
El Samad Y; Lanoix JP; Bennis Y; Diouf M; Saroufim C; Brunschweiler B; Rousseau F; Joseph C; Hamdad F; Ait Amer Meziane M; Routier S; Schmit JL
Antimicrob Agents Chemother; 2016 Oct; 60(10):6365-8. PubMed ID: 27458228
[TBL] [Abstract][Full Text] [Related]
14. High-dose regimen to achieve novel target trough concentration in teicoplanin.
Ueda T; Takesue Y; Nakajima K; Ichki K; Wada Y; Komatsu M; Tsuchida T; Takahashi Y; Ishihara M; Kimura T; Uchino M; Ikeuchi H
J Infect Chemother; 2014 Jan; 20(1):43-7. PubMed ID: 24462424
[TBL] [Abstract][Full Text] [Related]
15. Teicoplanin levels in bone and joint infections: are standard doses subtherapeutic?
Matthews PC; Taylor A; Byren I; Atkins BL
J Infect; 2007 Nov; 55(5):408-13. PubMed ID: 17825421
[TBL] [Abstract][Full Text] [Related]
16. Enhanced loading regimen of teicoplanin is necessary to achieve therapeutic pharmacokinetics levels for the improvement of clinical outcomes in patients with renal dysfunction.
Ueda T; Takesue Y; Nakajima K; Ichiki K; Doita A; Wada Y; Tsuchida T; Takahashi Y; Ishihara M; Ikeuchi H; Uchino M; Kimura T
Eur J Clin Microbiol Infect Dis; 2016 Sep; 35(9):1501-9. PubMed ID: 27278654
[TBL] [Abstract][Full Text] [Related]
17. Clinical efficacy and safety in patients treated with teicoplanin with a target trough concentration of 20 μg/mL using a regimen of 12 mg/kg for five doses within the initial 3 days.
Ueda T; Takesue Y; Nakajima K; Ichiki K; Ishikawa K; Takai Y; Yamada K; Tsuchida T; Otani N; Takahashi Y; Ishihara M; Takubo S; Ikeuchi H; Uchino M; Kimura T
BMC Pharmacol Toxicol; 2020 Jul; 21(1):50. PubMed ID: 32641110
[TBL] [Abstract][Full Text] [Related]
18. Teicoplanin in patients with acute leukaemia and febrile neutropenia: a special population benefiting from higher dosages.
Pea F; Viale P; Candoni A; Pavan F; Pagani L; Damiani D; Casini M; Furlanut M
Clin Pharmacokinet; 2004; 43(6):405-15. PubMed ID: 15086277
[TBL] [Abstract][Full Text] [Related]
19. Teicoplanin use in adult patients with haematological malignancy: Exploring relationships between dose, trough concentrations, efficacy and nephrotoxicity.
Byrne CJ; Egan S; Fennell JP; O'Byrne P; Enright H; Deasy E; Ryder SA; D'Arcy DM; McHugh J
Int J Antimicrob Agents; 2015 Oct; 46(4):406-12. PubMed ID: 26228465
[TBL] [Abstract][Full Text] [Related]
20. Population pharmacokinetics of teicoplanin administered by subcutaneous or intravenous route and simulation of optimal loading dose regimen.
Cazaubon Y; Venisse N; Mimoz O; Maire P; Ducher M; Bourguignon L; Goutelle S
J Antimicrob Chemother; 2017 Oct; 72(10):2804-2812. PubMed ID: 29091222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
